Acerta Pharma B.V. et al v. Cipla Limited et al
| Acerta Pharma B.V., AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB, Merck Sharp & Dohme B.V. and AstraZeneca Pharmaceuticals, LP |
| Cipla Limited and Cipla USA, Inc. |
| 1:2022cv00162 |
| February 4, 2022 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Gregory B Williams |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| Defendant |
Docket Report
RSS Track this Docket
This docket was last retrieved on September 7, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Case Reassigned to Judge Gregory B Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. Associated Cases: 1:22-cv-00154-RGA-SRF, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(apk) |
| Filing 33 NOTICE OF SERVICE of Plaintiffs' Initial Disclosures Pursuant to paragraph 4(a) of the Delaware Default Standard for Discovery filed by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V..(Silver, Daniel) |
| Filing 32 MOTION for Pro Hac Vice Appearance of Attorney Jihad Komis - filed by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Attachments: #1 Certification for Jihad Komis)(Joyce, Alexandra) |
SO ORDERED, re (27 in 22-cv-155-RGA; 28 in 22-cv-163-RGA; 36 in 22-cv-154-RGA; 32 in 22-cv-164-RGA; 32 in 22-cv-162-RGA) MOTION for Pro Hac Vice Appearance of Attorney Jihad Komis, filed by Merck Sharp & Dohme B.V., AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB, Acerta Pharma B.V.. Signed by Judge Richard G. Andrews on 6/22/2022. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(nms)
|
|
Filing 31
SCHEDULING ORDER: Joinder of Parties due by 1/9/2023. Amended Pleadings due by 1/9/2023. Fact Discovery completed by 2/12/2024. Joint Claim Construction Brief due by 7/31/2023. A Markman Hearing is set for 8/31/2023, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 2/21/2025, at 9:00 AM in Courtroom 6A. A 3 day Bench Trial on invalidity is set to start 3/3/2025, at 8:30 AM in Courtroom 6A. One day Bench Trials on infringement is set to start 3/10/2025, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 5/13/2022. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(nms)
|
| Filing 30 PROPOSED Scheduling Order, by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Joyce, Alexandra) Modified on 5/13/2022 (nms). |
| Minute Entry for proceedings held before Judge Richard G. Andrews - Rule 16(b) Telephone Scheduling Conference held on 5/11/2022. Counsel for Plaintiffs: A. Joyce. Counsel for Defendants: D. Gattuso, M. Haney, M. Goeller. A 3-day Bench Trial on Invalidity is scheduled to begin on 3/3/2025. A Pretrial Conference is set for 2/21/2025, at 9:00 AM. Plaintiff's are directed to resubmit the proposed scheduling order reflecting the rulings the Court made during the hearing. (Court Reporter Heather Triozzi.) Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(lak) |
| Filing 29 MOTION for Pro Hac Vice Appearance of Attorney Alexander S. Zolan - filed by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Joyce, Alexandra) |
|
SO ORDERED, re (D.I. 24 in 22-cv-155-RGA; D.I. 28 in 22-cv-154-RGA; D.I. 29 in 22-cv-164-RGA; D.I. 29 in 22-cv-162-RGA; D.I. 24 in 22-cv-163-RGA) MOTION for Pro Hac Vice Appearance of Attorney Alexander S. Zolan, filed by Merck Sharp & Dohme B.V., AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB, Acerta Pharma B.V.. Signed by Judge Richard G. Andrews on 5/10/2022. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(nms)
|
| Pro Hac Vice Attorney Alexander S. Zolan for Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, and Merck Sharp & Dohme B.V. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Filing 28 Letter to The Honorable Richard G. Andrews from Alexandra M. Joyce, Esq. regarding Dial-In for Rule 16 Teleconference. (Joyce, Alexandra) |
| Filing 27 PROPOSED Scheduling Order, by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Joyce, Alexandra) Modified on 5/10/2022 (nms). |
| Filing 26 NOTICE of Change of Address by Alexandra M. Joyce (Joyce, Alexandra) |
| Filing 25 STIPULATION TO EXTEND TIME the Deadline for Plaintiffs to Answer, Move, or Respond to the Counterclaims to May 16, 2022 - filed by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Joyce, Alexandra) |
|
SO ORDERED, re (D.I. 25 in 22-cv-162-RGA; D.I. 25 in 22-cv-164-RGA; D.I. 24 in 22-cv-154-RGA; D.I. 19 in 22-cv-163-RGA) STIPULATION and Proposed Order to Extend Time to Answer, Move, or Respond to the Counterclaims to May 16, 2022. Signed by Judge Richard G. Andrews on 4/28/2022. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(nms)
|
| Filing 24 REDACTED VERSION of #16 Answer to Complaint,, Counterclaim, by Cipla Limited, Cipla USA, Inc.. (Caponi, Steven) |
| Filing 23 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Cipla Limited, Cipla USA, Inc.. (Caponi, Steven) |
|
Filing 22
Order Setting Rule 16(b) Telephone Conference: A Scheduling Conference is set for 5/11/2022, at 3:00 PM before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 4/13/2022. (nms)
|
| Pro Hac Vice Attorneys Anil H. Patel, Jenna Bruce, Peter L. Giunta, and Harold M. Storey for Cipla Limited and Cipla USA, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
|
Filing 21
SO ORDERED Granting #15 Stipulation and [Proposed] Order Regarding Motion to Seal Defendants' Answer and Counterclaims. Signed by Judge Richard G. Andrews on 4/12/2022. (nms)
|
|
Filing 20
ORAL ORDER: The unopposed motion to seal the answer and counterclaims (D.I. #14 ) is GRANTED. Ordered by Judge Richard G. Andrews on 4/12/2022. (nms)
|
|
Filing 19
ORAL ORDER: The six exhibits found at D.I. #16 are STRUCK. They are absolutely superfluous to the counterclaims stating claims, and completely unnecessary at the pleading stage. Ordered by Judge Richard G. Andrews on 4/12/2022. (nms)
|
| Filing 18 Letter to the Honorable Richard G. Andrews, from Steven L. Caponi, regarding Exhibits 1-6 to Defendants' counterclaims. (Caponi, Steven) Modified on 4/12/2022 (nms). |
|
Filing 17
ORAL ORDER: Defendants are requested to respond to why I should not simply strike Exhibits 1-6 as being unnecessary to the Answer. Ordered by Judge Richard G. Andrews on 4/12/2022. (nms)
|
| Filing 16 [SEALED] ANSWER to #1 Complaint, with Jury Demand, and COUNTERCLAIMS against Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V. by Cipla Limited, Cipla USA, Inc.. (Caponi, Steven) Modified on 4/11/2022 (nms). Modified on 4/12/2022 (nms). |
| Filing 15 STIPULATION and [Proposed] Order Regarding Motion to Seal Defendants' Answer, Counterclaims, and Exhibits, by Cipla Limited, Cipla USA, Inc.. (Goeller, Matthew) Modified on 4/11/2022 (nms). |
| Filing 14 Unopposed Motion to File Under Seal - filed by Cipla Limited, Cipla USA, Inc.. (Attachments: #1 Proposed Order, #2 7.1.1 Certificate)(Goeller, Matthew) Modified on 4/11/2022 (nms). |
| Filing 13 MOTION for Pro Hac Vice Appearance of Attorney Anil H. Patel, Harold Storey, Jenna Bruce and Peter Giunta - filed by Cipla Limited, Cipla USA, Inc.. (Caponi, Steven) |
|
SO ORDERED, re #13 MOTION for Pro Hac Vice Appearance of Attorney Anil H. Patel, Harold Storey, Jenna Bruce and Peter Giunta, filed by Cipla Limited, Cipla USA, Inc.. Signed by Judge Richard G. Andrews on 4/7/2022. (nms)
|
| Pro Hac Vice Attorney Kevin Hoagland-Hanson, Min Kyung Jeon, Stanley E. Fisher, David I. Berl, and Sarahi Uribe for Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V., added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(smg) |
|
SO ORDERED, re #12 STIPULATION and Proposed Order Extending Time for Response to Complaint (*Reset Answer Deadlines: Cipla Limited answer due 4/11/2022; Cipla USA, Inc. answer due 4/11/2022). Signed by Judge Richard G. Andrews on 2/23/2022. (nms)
|
| Filing 12 STIPULATION and Proposed Order Extending Time for Response to Complaint - filed by Cipla Limited, Cipla USA, Inc.. (Caponi, Steven) Modified on 2/23/2022 (nms). |
| Filing 11 MOTION for Pro Hac Vice Appearance of Attorney David I. Berl, Stanley E. Fisher, Kevin Hoagland-Hanson, Sarahi Uribe, and Min Kyung Jeon - filed by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Attachments: #1 Certifications for David I. Berl, Stanley E. Fisher, Kevin Hoagland-Hanson, Sarahi Uribe, and Min Kyung Jeon)(Joyce, Alexandra) |
|
SO ORDERED, re (12 in 22-cv-164-RGA; 11 in 22-cv-155-RGA; 11 in 22-cv-162-RGA; 11 in 22-cv-163-RGA; 11 in 22-cv-154-RGA) MOTION for Pro Hac Vice Appearance of Attorney David I. Berl, Stanley E. Fisher, Kevin Hoagland-Hanson, Sarahi Uribe, and Min Kyung Jeon, filed by Merck Sharp & Dohme B.V., AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB, Acerta Pharma B.V.. Signed by Judge Richard G. Andrews on 2/17/2022. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(nms)
|
| Filing 10 DECLARATION of Service of Cipla Limited, by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Attachments: #1 Exhibits A-B)(Joyce, Alexandra) Modified on 2/9/2022 (nms). |
| Filing 9 DECLARATION of Service of Cipla USA, Inc., by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Attachments: #1 Exhibits A-B)(Joyce, Alexandra) Modified on 2/9/2022 (nms). |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA (rjb) |
| Filing 8 Summons Issued with Magistrate Consent Notice attached as to Cipla Limited on 2/4/2022. (srs) |
| Filing 7 Summons Issued with Magistrate Consent Notice attached as to Cipla USA, Inc. on 2/4/2022. (srs) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited filed by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (srs) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Merck & Co., Inc. for Merck Sharp & Dohme B.V. filed by Merck Sharp & Dohme B.V. (srs) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,758,524 ;10,239,883 ;9,796,721 ;10,167,291 ;10,272,083. (srs) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than December 29, 2021. Date of Expiration of Patent: 9,758,524 - July 11, 2032, 10,239,883- July 11, 2032, 9,796,721 - July 1, 2036, 10,167,291 - July 1, 2036, 10,272,083 January 21, 2035. Thirty Month Stay Deadline: No Earlier than April 30, 2025. |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) |
| Filing 1 COMPLAINT filed against Cipla Limited and Cipla USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3796360.) - filed by AstraZeneca UK Limited, Acerta Pharma B.V., AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme B.V., and AstraZeneca AB. (Attachments: #1 Exhibit A-F, #2 Civil Cover Sheet)(srs) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
